ストックスクリーナーアプリを入手
18.30
0.34%
0.0683
前日終値:
$18.23
開ける：
$18.28
24時間の取引高:
6,890
Relative Volume:
0.10
時価総額：
$198.11M
収益：
$19.85M
当期純損益:
$-12.75M
株価収益率:
-13.26
EPS:
-1.38
ネットキャッシュフロー:
$-21.94M
1週間 パフォーマンス:
+8.05%
1か月 パフォーマンス:
-2.49%
6か月 パフォーマンス:
+3.41%
1年 パフォーマンス:
+21.14%
1日の値動き範囲:
$18.18
$18.40
1週間の範囲:
$16.00
$18.40
52週間の値動き範囲:
$12.78
$24.00
Mediwound Ltd Stock (MDWD) Company Profile
MDWD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
18.30 | 198.11M | 19.85M | -12.75M | -21.94M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.43 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.17 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
602.20 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.01 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.60 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | 開始されました | Craig Hallum | Buy |
| 2024-07-16 | 繰り返されました | Maxim Group | Buy |
| 2022-12-22 | 開始されました | Maxim Group | Buy |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2020-09-23 | 開始されました | BTIG Research | Buy |
| 2016-11-28 | 開始されました | Aegis Capital | Buy |
| 2016-08-17 | 開始されました | Wells Fargo | Outperform |
| 2014-04-16 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Mediwound Ltd (MDWD) 最新ニュース
MediWound (NASDAQ:MDWD) shareholder returns have been respectable, earning 53% in 5 years - Simply Wall St
MediWound (MDWD) Projected to Post Earnings on Wednesday - Defense World
MediWound Ltd. (NASDAQ:MDWD) Shares Acquired by Rhumbline Advisers - Defense World
MediWound Ltd. to Host Earnings Call - ACCESS Newswire
MediWound at TD Cowen Conference: Strategic Insights on Growth - Investing.com India
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
When Will MediWound Reveal Its 2024 Financial Performance? Key Date Announced - StockTitan
MediWound (NASDAQ:MDWD) Research Coverage Started at Craig Hallum - Defense World
MediWound (NASDAQ:MDWD) Now Covered by Analysts at Craig Hallum - MarketBeat
Craig-Hallum sets $39 target on MediWound stock with buy rating - Investing.com Canada
(MDWD) Investment Report - Stock Traders Daily
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Craig-Hallum sets $39 target on MediWound stock with buy rating By Investing.com - Investing.com South Africa
Laurentian Bank of Canada declares dividend on its common shares - The Globe and Mail
Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical - openPR
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care - GlobeNewswire
Can NexoBrid Transform Pediatric Burn Care? Phase III Results Show Superiority - StockTitan
MediWound to Present at the 45th Annual TD Cowen Health Care Conference - GlobeNewswire
Can MediWound's Tissue Repair Innovation Reshape the Healthcare Market? CEO Reveals Strategy - StockTitan
(MDWD) Trading Signals - Stock Traders Daily
MediWound stock climbs 4% on Phase 3 study initiation - MSN
MediWound begins pivotal Phase III trial for wound therapy By Investing.com - Investing.com Nigeria
MediWound begins pivotal Phase III trial for wound therapy - MSN
MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers - Marketscreener.com
Mediwound’s EscharEx Shows Promising Results in Phase 3 Trial - TipRanks
MediWound Launches Phase III Trial for EscharEx Targeting Venous Leg Ulcers - TipRanks
MediWound to launch Phase III trial for venous leg ulcers -February 12, 2025 at 07:00 am EST - Marketscreener.com
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers - GlobeNewswire
EscharEx Clinical Trial: MediWound's Groundbreaking Solution for $375M Venous Ulcer Market - StockTitan
Is MediWound (NASDAQ:MDWD) In A Good Position To Invest In Growth? - Simply Wall St
JPMorgan Chase & Co. Has $61,000 Stock Position in MediWound Ltd. (NASDAQ:MDWD) - MarketBeat
How the (MDWD) price action is used to our Advantage - Stock Traders Daily
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive: MediWound CEO to Reveal Latest Tissue Repair Innovations at Major Healthcare Conference - StockTitan
JPMorgan Chase & Co. Sells 75,360 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week - Yahoo Finance
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains? - Yahoo Finance
Barclays PLC Increases Stock Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
BioHarvest Sciences Strengthens Board with Healthcare Industry Veteran Sharon Malka - StockTitan
Burns Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corp - The Globe and Mail
Trading (MDWD) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for MediWound (NASDAQ:MDWD) - Defense World
MediWound (NASDAQ:MDWD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions - Yahoo Finance
MediWound Ltd.'s (NASDAQ:MDWD) P/S Still Appears To Be Reasonable - Simply Wall St
Geode Capital Management LLC Sells 2,365 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
Barclays PLC Raises Stake in MediWound Ltd. (NASDAQ:MDWD) - Defense World
When (MDWD) Moves Investors should Listen - Stock Traders Daily
Mediwound Ltd (MDWD) 財務データ
収益
当期純利益
現金流量
EPS
1.28%
0.80%
大文字化:
|
ボリューム (24 時間):